The model achieved significantly better results compared to PD-L1 prediction value alone, which is the only biomarker currently used by physicians in clinical practice to select NSCLC patients for IO with an accuracy of ACC = 0.655 on the analyzed dataset. This evidence concerns the gene CD274 and non-small cell lung carcinoma.